86627-01-2

Upstream product

• 86626-96-2 (6-Chloro-2-methylsulfanyl-pyrimidin-4-yl)-(2,3-dimethyl-phenyl)-methyl-amine 
• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 41456-51-3 N-methyl-2,3-dimethylaniline 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 

Downstream Products

• 86627-31-8 ethyl [4-chloro-6-(N-methyl-2,3-xylidino)-2-pyrimidinyl]oxyacetate 
• 86627-32-9 [4-chloro-6-(N-methyl-2,3-xylidino)-2-pyrimidinyl]-oxyacetic acid 
• 86627-19-2 N-[4-chloro-6-(N-methyl-2,3-xylidino)-2-pyrimidinyl]-aminoacetic acid 
• 86627-51-2 6-Chloro-N⁴-(2,3-dimethyl-phenyl)-N²,N²,N⁴-trimethyl-pyrimidine-2,4-diamine 
• 86627-20-5 N-[4-chloro-6-(N-methyl-2,3-xylidino)-2-pyrimidinyl]-aminoacetic acid, ethyl ester 

Relevant academic research and scientific papers

Pyrimidine and s-triazine derivatives with antilipidemic activity

Pyrimidine and s-triazine derivatives of formula (I) (I) in which X=CH or N; Y=for example halogen, alkoxy; W=for example -S-CH2-COOH, -O-CH2-COO alkyl, -NH-CH2-CONHCH2CH2OH; Z=for example 2,3-xylidino, and methods for the preparation thereof are described. The compounds show high antilipemic activity.

Novel pyrimidine and 1,3,5-triazine hypolipidemic agents

New compounds were synthesized by changing the substituents of a trisubstituted pyrimidine, i.e., [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid, a potent hypolipidemic agent, impaired, however, by a marked hepatomegaly-inducing effect. The structural variations led to the subsidence (14b, i.e., 4-chloro-2-(dimethylamino)-6-[(2,3-dimethylphenyl)amino]pyrimidine) or to the reduction (18b, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]amino]acetic acid) of said untoward effect but still maintained the hypolipidemic effect that, although markedly decreased, still proves significant for serum cholesterol and triglycerides (18b) or for serum triglycerides only (14b).